Form 4: Samsara BioCapital Increases Stake in Mineralys Therapeutics with $8.1 Million Purchase

Samsara BioCapital, a significant shareholder in Mineralys Therapeutics, has increased its holdings through a recent purchase of 600,000 shares of common stock.

Summary

• Samsara BioCapital GP, LLC, and Samsara BioCapital, L.P. have filed a Form 4 detailing changes in their beneficial ownership of Mineralys Therapeutics, Inc. (MLYS) common stock.
• On March 13, 2025, Samsara BioCapital, L.P. purchased 600,000 shares of MLYS common stock at a price of $13.50 per share, totaling $8,100,000.
• Following this transaction, Samsara BioCapital, L.P. beneficially owns 5,674,916 shares of MLYS common stock.
• Samsara BioCapital GP, LLC, as the general partner of Samsara BioCapital, L.P., may be deemed to beneficially own these shares but disclaims beneficial ownership except to the extent of its pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a major shareholder is increasing their investment, suggesting confidence in the company's prospects. However, it's a routine filing, so the impact is limited.

Positives

• Increased investment by a major shareholder, Samsara BioCapital, could signal confidence in Mineralys Therapeutics' future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders and major shareholders. This filing indicates increased investment by a significant shareholder, which can be viewed positively by the market.

Stakeholder Impact

• The increased investment by Samsara BioCapital could positively influence shareholder confidence.

Key Dates